167 related articles for article (PubMed ID: 38736638)
1. Computational structural genomics and clinical evidence suggest BCKDK gain-of-function may cause a potentially asymptomatic maple syrup urine disease phenotype.
Singh E; Chi YI; Kopesky J; Zimmerman M; Urrutia R; Basel D; Schwoerer JS
JIMD Rep; 2024 May; 65(3):144-155. PubMed ID: 38736638
[TBL] [Abstract][Full Text] [Related]
2. A Gain-of-Function Mutation on
Maguolo A; Rodella G; Giorgetti A; Nicolodi M; Ribeiro R; Dianin A; Cantalupo G; Monge I; Carcereri S; De Bernardi ML; Delledonne M; Pasini A; Campostrini N; Ion Popa F; Piacentini G; Teofoli F; Vincenzi M; Camilot M; Bordugo A
Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205278
[TBL] [Abstract][Full Text] [Related]
3. Dataset reporting BCKDK interference in a BCAA-catabolism restricted environment.
Bravo-Alonso I; Oyarzabal A; Sánchez-Aragó M; Rejas MT; Merinero B; García-Cazorla A; Artuch R; Ugarte M; Rodríguez-Pombo P
Data Brief; 2016 Jun; 7():755-9. PubMed ID: 27054191
[TBL] [Abstract][Full Text] [Related]
4. Clues and challenges in the diagnosis of intermittent maple syrup urine disease.
Pode-Shakked N; Korman SH; Pode-Shakked B; Landau Y; Kneller K; Abraham S; Shaag A; Ulanovsky I; Daas S; Saraf-Levy T; Reznik-Wolf H; Vivante A; Pras E; Almashanu S; Anikster Y
Eur J Med Genet; 2020 Jun; 63(6):103901. PubMed ID: 32151765
[TBL] [Abstract][Full Text] [Related]
5. Maple syrup urine disease: magnetic resonance imaging findings in three patients.
Allahwala A; Ahmed S; Afroze B
J Pak Med Assoc; 2021 Apr; 71(4):1309-1313. PubMed ID: 34125801
[TBL] [Abstract][Full Text] [Related]
6. Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation.
Deon M; Guerreiro G; Girardi J; Ribas G; Vargas CR
Int J Dev Neurosci; 2023 Oct; 83(6):489-504. PubMed ID: 37340513
[TBL] [Abstract][Full Text] [Related]
7. Maple syrup urine disease: mechanisms and management.
Blackburn PR; Gass JM; Vairo FPE; Farnham KM; Atwal HK; Macklin S; Klee EW; Atwal PS
Appl Clin Genet; 2017; 10():57-66. PubMed ID: 28919799
[TBL] [Abstract][Full Text] [Related]
8. Maple syrup urine disease decompensation misdiagnosed as a psychotic event.
Higashimoto T; Whitehead MT; MacLeod E; Starin D; Regier DS
Mol Genet Metab Rep; 2022 Sep; 32():100886. PubMed ID: 35756860
[TBL] [Abstract][Full Text] [Related]
9. Maple syrup urine disease due to a paracentric inversion of chr 19 that disrupts
Yokoi K; Nakajima Y; Sudo Y; Mariya T; Kawamura R; Tsutsumi M; Inagaki H; Yoshikawa T; Ito T; Kurahashi H
JIMD Rep; 2022 Nov; 63(6):575-580. PubMed ID: 36341163
[TBL] [Abstract][Full Text] [Related]
10. Lipid changes in the metabolome of a single case study with maple syrup urine disease (MSUD) after five days of improved diet adherence of controlled branched-chain amino acids (BCAA).
Douglas TD; Newby LK; Eckstrand J; Wixted D; Singh RH
Mol Genet Metab Rep; 2020 Dec; 25():100651. PubMed ID: 33088714
[TBL] [Abstract][Full Text] [Related]
11. PPM1K defects cause mild maple syrup urine disease: The second case in the literature.
Ozcelik F; Arslan S; Ozguc Caliskan B; Kardas F; Ozkul Y; Dundar M
Am J Med Genet A; 2023 May; 191(5):1360-1365. PubMed ID: 36706222
[TBL] [Abstract][Full Text] [Related]
12. Two novel compound heterozygous mutations in the BCKDHB gene that cause the intermittent form of maple syrup urine disease.
Guo Y; Liming L; Jiang L
Metab Brain Dis; 2015 Dec; 30(6):1395-400. PubMed ID: 26239723
[TBL] [Abstract][Full Text] [Related]
13. Two novel mutations in the BCKDHB gene that cause maple syrup urine disease.
Han B; Han B; Guo B; Liu Y; Cao Z
Pediatr Neonatol; 2018 Oct; 59(5):515-519. PubMed ID: 29366676
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiology of maple syrup urine disease: Focus on the neurotoxic role of the accumulated branched-chain amino acids and branched-chain α-keto acids.
Amaral AU; Wajner M
Neurochem Int; 2022 Jul; 157():105360. PubMed ID: 35577033
[TBL] [Abstract][Full Text] [Related]
15. Total branched-chain amino acids requirement in patients with maple syrup urine disease by use of indicator amino acid oxidation with L-[1-13C]phenylalanine.
Riazi R; Rafii M; Clarke JT; Wykes LJ; Ball RO; Pencharz PB
Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E142-9. PubMed ID: 14970005
[TBL] [Abstract][Full Text] [Related]
16. A new missense mutation in the BCKDHB gene causes the classic form of maple syrup urine disease (MSUD).
Miryounesi M; Ghafouri-Fard S; Goodarzi H; Fardaei M
J Pediatr Endocrinol Metab; 2015 May; 28(5-6):673-5. PubMed ID: 25381949
[TBL] [Abstract][Full Text] [Related]
17. Plasma amino acid and urine organic acid profiles of Filipino patients with maple syrup urine disease (MSUD) and correlation with their neurologic features.
Chiong MA; Tan MA; Cordero CP; Fodra EG; Manliguis JS; Lopez CP; Dalmacio LM
Mol Genet Metab Rep; 2016 Dec; 9():46-53. PubMed ID: 27761412
[TBL] [Abstract][Full Text] [Related]
18. Maple syrup urine disease: further evidence that newborn screening may fail to identify variant forms.
Puckett RL; Lorey F; Rinaldo P; Lipson MH; Matern D; Sowa ME; Levine S; Chang R; Wang RY; Abdenur JE
Mol Genet Metab; 2010 Jun; 100(2):136-42. PubMed ID: 20307994
[TBL] [Abstract][Full Text] [Related]
19. Haemodialysis is an effective treatment in acute metabolic decompensation of maple syrup urine disease.
Atwal PS; Macmurdo C; Grimm PC
Mol Genet Metab Rep; 2015 Sep; 4():46-8. PubMed ID: 26937409
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
